Klin Farmakol Farm. 2021;35(3):49-55 | DOI: 10.36290/far.2021.017

Analysis of antibiotic consumption in the Czech Republic and its conclusions for clinical practice

Petr Domecký1, Lenka Suchopárová1, 2, Josef Malý1, 3
1 Katedra sociální a klinické farmacie, Farmaceutická fakulta UK v Hradci Králové
2 Nemocniční lékárna, Fakultní nemocnice v Motole, Praha
3 Oddělení klinické farmacie, Nemocniční lékárna, Fakultní nemocnice v Motole, Praha

Introduction: Antibiotics (ATB) are essential medicines and have unquestionable uses. Unfortunately, the irrational use of ATB leads to the risks of adverse effects, interactions, and the development of drug resistance. This study aimed to analyse ATB consumption for systemic use in the Czech Republic (CR) in 2005-2019 and provide conclusions for clinical practice.

Methods: The analysis of ATB consumption for systemic use was performed as a longitudinal retrospective analysis of data from the State Institute for Drug Control database in the years 2005-2019 using the standard methodology for studying drug consumption of the DUR (Drug Utilization Review) type. ATB consumption was calculated as defined daily doses (DDD) of each ATB per thousand inhabitants per day (TID). The total consumption of ATB for systemic use in each year was analysed. Secondarily, consumption for individual representatives or subgroups was analysed and relative quality indicators of ATB consumption were evaluated.

Results: The highest consumption of ATB for systemic use was observed in 2015 when it reached 19.3338 DDD/TID. β-lactam ATB (penicillins) was the most commonly used group of ATB throughout the study period. The most significant change in consumption over the period was in the fluoroquinolone group, where the decrease from 2005 to 2019 was more than 2-fold. The obvious was the downward trend in consumption of norfloxacin, which occurred in 2013. ATB consumption increased mainly for meropenem, vancomycin, cefuroxime-axetil, β-Lactamase-protected penicillins and the 2nd and 3rd generation cephalosporins.

Conclusion: In the overall assessment, CR was not among the countries with high ATB consumption and frequent negative results in the relative quality indicators of ATB consumption. In particular, the possible irrational substitution of some ATB and an increase in the consumption of some broad-spectrum ATB was observed in CR.

Keywords: drug utilization review, anti‑bacterial agents, drug resistance.

Published: November 8, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Domecký P, Suchopárová L, Malý J. Analysis of antibiotic consumption in the Czech Republic and its conclusions for clinical practice. Klin Farmakol Farm. 2021;35(3):49-55. doi: 10.36290/far.2021.017.
Download citation

References

  1. Beneš J. Antibiotika - systematika, vlastnosti, použití. Prague (CZ): Grada Publishing, 2018. ISBN 978-80-271-0636-3.
  2. Jindrák V, Hedlová D, Urbášková P. Antibiotická politika a prevence infekcí v nemocnici. Prague (CZ): Mladá fronta, 2014. Aeskulap. ISBN 978-80-204-2815-8.
  3. Antibiotická politika ČR [internet]. Praha: Státní ústav pro kontrolu léčiv 2010 [cit. 14-07-2021]. Dostupné na: http://www.sukl.cz/antibioticka‑politika‑cr.
  4. Šturma J. Činnosti a funkce NAP [internet]. Státní zdravotní ústav 2010. [cit. 14-07-2021]. Dostupné na: http://www.szu.cz/tema/cinnosti‑a‑funkce.
  5. Akční plán antibiotického programu České republiky (AP NAP) na období 2019-2022 [internet]. Ministerstvo zdravotnictví ČR 2019. [cit. 14-07-2021]. Dostupné na: https://www.mzcr.cz/wp‑content/uploads/wepub/7725/36701/Ak%C4%8Dn%C3%AD%20 pl%C3%A1n%20NAP%202019-22.pdf.
  6. Gilbert DN, Chambers HF, Eliopoulos GM et al. The Sanford Guide to Antimicrobial Therapy 2019: 50 Years: 1969-2019. Sperryville (USA). Antimicrobial Therapy, Incorporated, 2019. 978-1-944272-09-8.
  7. Shamna M, Dilip C, Ajmal M et al. A prospective study on Adverse Drug Reactions of antibiotics in tertiary care hospital. Saudi Pharm J. 2014 Sep; 22(4): 303-308. Go to original source... Go to PubMed...
  8. Paterová P, Králíčková P, Vávrová P et al. Principy racionální léčby antibiotiky (část II.). Interv Akut Kardiol. 2016; 15(2): 90-93. Go to original source...
  9. Antibiotic resistance [internet]. World Health Organization 2018 [cit. 14-07-2021]. Dostupné na: https://www.who.int/news‑room/fact‑sheets/detail/antibiotic‑resistance.
  10. Cox G, Wright GD. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int J Med Microbiol. 2013 Aug; 303(6-7): 287-292. Go to original source... Go to PubMed...
  11. Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016 Apr;4(2):10.1128/microbiolspec.VMBF-0016-2015. Go to original source...
  12. Friedman ND, Temkin E, Carmeli Y. The negative impact of antibiotic resistance. Clin Microbiol Infect. 2016 May; 22(5): 416-422. Go to original source... Go to PubMed...
  13. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014 Dec; 5(6): 229-241. Go to original source... Go to PubMed...
  14. Počet a pohyb obyvatelstva [internet]. Český statistický úřad. [cit. 14-07-2021]. Dostupné na: https://vdb.czso.cz/vdbvo2/faces/cs/index.jsf?page=statistiky & katalog=30845#katalog=33155.
  15. Quality indicators for antibiotic consumption in the community [internet]. European Centre for Disease Prevention and Control (ECDC) 2020. [cit. 14-07-2021]. Dostupné na: https://www.ecdc.europa.eu/en/antimicrobial‑consumption/database/quality‑indicators.
  16. Anatomicko‑terapeuticko‑chemická klasifikace [internet]. Státní ústav pro kontrolu léčiv. [cit. 14-07-2021]. Dostupné na: https://www.sukl.cz/modules/medication/atc_tree.php?current=J01C#J01C.
  17. Antimicrobial consumption - Annual Epidemiological Report for 2019 [internet]. European Centre for Disease Prevention and Control (ECDC) 2020. [cit. 14-07-2021]. Dostupné na: *Antimicrobial consumption in the EU and EEA: Annual Epidemiological Report 2019 (europa.eu).
  18. Surveillance of antimicrobial resistence in Europe 2018 [internet]. European Centre for Disease Prevention and Control (ECDC) 2020. [cit. 14-07-2021]. Dostupné na: https://www.ecdc.europa.eu/en/publications‑data/surveillance‑antimicrobial‑resistance‑europe-2018.
  19. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb‑Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL; Burden of AMR Collaborative Group. Attributable deaths and disability‑adjusted life‑years caused by infections with antibiotic‑resistant bacteria in the EU and the European Economic Area in 2015: a population‑level modelling analysis. Lancet Infect, DiS. 2019 Jan; 19(1): 56-66. Go to original source... Go to PubMed...
  20. Nýč O, Urbášková P, Marešová V a kol. Konsensus používání antibiotik III. Chinolony. Prakt Lék 2006; 86(10): 570-574.
  21. Konsensus používání antibiotik: Fluorochinolonů 2019 [internet]. Česká lékařská společnost Jana Evangelisty Purkyně, Subkomise pro antibiotickou politiku (SKAP). [cit. 14-07-2021]. Dostupné na: https://www.cls.cz/antibioticka‑politika‑a.
  22. Vachek J, Zakiyanov O, Adámková V et al. Infekce dolních a horních močových cest. Kardiol Rev Int Med 2014; 16(1): 74-77.
  23. Důležitá upozornění - nežádoucí účinky léčiv [internet]. Státní ústav pro kontrolu léčiv. [cit. 24-08-2021]. Dostupné na: https://www.sukl.cz/chinolonova‑a‑fluorochinolonova‑antibiotika‑omezeni?highlightWords=fluorochinolonov%C3%A1
  24. Detail léčivého přípravku [internet]. Gyrablock. Státní ústav pro kontrolu léčiv. [cit. 14-07-2021] Dostupné na: https://www.sukl.cz/modules/medication/detail.php?kod=0044087.
  25. Přijatá oznámení o zahájení, přerušení, obnovení nebo ukončení uvádění léčivého přípravku na trh [internet]. Státní ústav pro kontrolu léčiv. [cit. 14-07-2021]. Dostupné na: https://prehledy.sukl.cz/mr.html#/.
  26. Antibiotika musí být používána s rozmyslem. Pediatr. praxi 2015; 16(5): 355-356.
  27. Souhrn údajů o přípravku [internet]. Chloramphenicol Vuab. VUAB Pharma, a. s., Vltavská 53, 252 63 Roztoky, Česká republika. Datum revize textu: 14-05-2021. [cit. 14-07-2021]. Dostupné na: https://www.sukl.cz/modules/medication/download.php?file=SPC172235.pdf & type=spc & as=chloramphenicol‑vuab‑spc.
  28. EudraVigilance - European database of suspected adverse drug reaction reports. Chloramphenicol [internet]. [cit. 14-07-2021]. Dostupné na: http://www.adrreports.eu/en/search.html.
  29. Doporučený postup diagnostiky a léčby kolitidy vyvolané Clostridium difficile (červen 2014) [internet]. Společnost infekčního lékařství. Česká lékařská společnost Jana Evangelisty Purkyně. [cit. 14-07-2021]. Dostupné na: https://www.infekce.cz/dpCDI14.htm.
  30. Konsensus cefalosporiny 2016 [internet]. Česká lékařská společnost Jana Evangelisty Purkyně, Subkomise pro antibiotickou politiku. [cit. 14-07-2021]. Dostupné na: https://www.cls.cz/antibioticka‑politika‑a.
  31. Sedláčková L. Alergie na beta‑laktamová antibiotika dnes. Med. praxi 2017; 14(4): 193-195.
  32. Polanecký V, Göpfertová D. Manuál praktické epidemiologie - díl 1. Prague (CZ): IPVZ, 2015. ISBN 978-80-87023-37-2.
  33. Farmakoterapeutické informace - měsíčník pro lékaře a farmaceuty [internet]. Státní ústav pro kontrolu léčiv. Farmakoterapeutické informace 2/2020. [cit. 14-07-2021]. Dostupné na: https://www.sukl.cz/sukl/2020.




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.